Utility of plasma Neurofilament light as a diagnostic and prognostic biomarker of the postural instability gait disorder motor subtype in early Parkinson’s disease

Table 2 Multivariable analysis on baseline plasma NfL levels with cognitive and motor outcomes in PD patients

Group	MDS-UPDRS Part III (Motor)^a	H&Y	MoCA
Group	β^b (95% CI)	β (95% CI)	β (95% CI)
Total PD	−0.567 (−4.775, 3.642)	− 0.029 (− 0.214, 0.157)	−0.455 (− 1.995, 1.086)
TD	−6.815 (− 14.036, 0.407)	− 0.188 (− 0.498, 0.121)	1.437 (− 0.757, 3.631)
PIGD	10.687** (3.325, 18.050)	0.292 (− 0.021, 0.605)	−3.168* (− 5.954, − 0.382)

Abbreviations: PD Parkinson’s Disease; TD Tremor-Dominant; PIGD Postural Instability Gait Disorder; H&Y stage Hoehn and Yahr stage; MDS-UPDRS Movement Disorder Society Unified Parkinson’s Disease Rating Scale; MoCA Montreal Cognitive Assessment; CI Confidence Interval; NfL, Neurofilament light chain protein
^a MDS-UPDRS Part III (Motor) scores, H&Y stages and MoCA scores of PD patients are the outcome variables
^b Beta coefficient (and 95% CI) of Ln-NfL level; Multivariable linear regression adjusted for age, sex and disease duration
* P < 0.05, ** P < 0.01

ISSN: 1750-1326